Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ$131.255-0.11 (-0.08%)
Market Cap
$13.97B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
657 of 924
Rank in Industry
41 of 56
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ITCI Insider Trading Activity
ITCI Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $36,905,100 | 15 | 100 |
Related Transactions
| RIGGS RORY B | director | 0 | $0 | 1 | $337,193 | $-337,193 |
| Neumann Mark | EVP, Chief Commercial Officer | 0 | $0 | 1 | $1.41M | $-1.41M |
| VAN NOSTRAND ROBERT L | director | 0 | $0 | 1 | $1.52M | $-1.52M |
| Halstead Michael | President | 0 | $0 | 2 | $3.69M | $-3.69M |
| Mates Sharon | Chairman and CEO | 0 | $0 | 10 | $29.95M | $-29.95M |
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as …
Insider Activity of Intra-Cellular Therapies, Inc.
Over the last 12 months, insiders at Intra-Cellular Therapies, Inc. have bought $0 and sold $36.91M worth of Intra-Cellular Therapies, Inc. stock.
On average, over the past 5 years, insiders at Intra-Cellular Therapies, Inc. have bought $4.11M and sold $35.34M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 99,000 shares for transaction amount of $2.93M was made by Alafi Christopher D (director) on 2020‑09‑14.
List of Insider Buy and Sell Transactions, Intra-Cellular Therapies, Inc.
| 2024-12-05 | Sale | Mates Sharon | Chairman and CEO | 51,697 0.0486% | $84.08 | $4.35M | +51.05% | |
| 2024-12-04 | Sale | Mates Sharon | Chairman and CEO | 51,000 0.048% | $85.80 | $4.38M | +47.78% | |
| 2024-11-13 | Sale | Halstead Michael | President | 18,714 0.0175% | $88.38 | $1.65M | +43.26% | |
| 2024-11-12 | Sale | Halstead Michael | President | 22,869 0.0216% | $89.12 | $2.04M | +42.68% | |
| 2024-08-30 | Sale | Mates Sharon | Chairman and CEO | 34,396 0.0324% | $72.84 | $2.51M | +16.37% | |
| 2024-08-29 | Sale | Mates Sharon | Chairman and CEO | 35,604 0.0338% | $72.57 | $2.58M | +17.96% | |
| 2024-08-28 | Sale | Mates Sharon | Chairman and CEO | 32,699 0.0309% | $72.75 | $2.38M | +17.05% | |
| 2024-08-27 | Sale | Mates Sharon | Chairman and CEO | 40,513 0.0382% | $73.58 | $2.98M | +15.20% | |
| 2024-08-26 | Sale | Mates Sharon | Chairman and CEO | 22,713 0.0215% | $74.59 | $1.69M | +14.18% | |
| 2024-08-23 | Sale | Mates Sharon | Chairman and CEO | 28,680 0.0271% | $74.46 | $2.14M | +14.11% | |
| 2024-08-22 | Sale | Mates Sharon | Chairman and CEO | 39,380 0.0374% | $74.68 | $2.94M | +14.28% | |
| 2024-08-21 | Sale | Mates Sharon | Chairman and CEO | 53,013 0.0501% | $75.65 | $4.01M | +12.25% | |
| 2024-08-16 | Sale | Neumann Mark | EVP, Chief Commercial Officer | 18,714 0.0178% | $75.08 | $1.41M | +13.32% | |
| 2024-06-24 | Sale | RIGGS RORY B | director | 4,462 0.0042% | $75.57 | $337,193 | +8.67% | |
| 2024-06-18 | Sale | VAN NOSTRAND ROBERT L | director | 20,000 0.0208% | $75.91 | $1.52M | +7.10% | |
| 2024-03-11 | Sale | Mates Sharon | Chairman, President & CEO | 20,565 0.0212% | $65.21 | $1.34M | +15.64% | |
| 2024-03-11 | Sale | Neumann Mark | EVP, Chief Commercial Officer | 7,345 0.0076% | $65.61 | $481,931 | +15.64% | |
| 2024-03-11 | Sale | Durgam Suresh K. | EVP, Chief Medical Officer | 3,712 0.0038% | $65.59 | $243,482 | +15.64% | |
| 2024-03-11 | Sale | Hineline Lawrence J. | SVP of Finance, CFO | 10,121 0.0105% | $65.96 | $667,587 | +15.64% | |
| 2024-03-11 | Sale | Halstead Michael | EVP and General Counsel | 7,345 0.0076% | $65.97 | $484,537 | +15.64% |
Total: 265
*Gray background shows transactions not older than one year
Insider Historical Profitability
44.65%
| RIGGS RORY B | director | 116600 0.1097% | $15.32M | 2 | 2 | +11.52% |
| VAN NOSTRAND ROBERT L | director | 9690 0.0091% | $1.27M | 1 | 4 | +35.53% |
| Halstead Michael | President | 0 0% | $0 | 2 | 31 | +67.15% |
| ALAFI MOSHE | 10 percent owner | 3953270 3.718% | $519.3M | 12 | 1 | +49.4% |
| ALAFI CAPITAL CO LLC | 10 percent owner | 3953270 3.718% | $519.3M | 12 | 0 | +49.4% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$910,099,463 | 123 | 11.52% | $2.54B | |
$12,681,496 | 70 | 20.90% | $810.72M | |
$14,599,168 | 59 | 12.79% | $1.34B | |
$23,522,750 | 59 | -6.74% | $5.1B | |
Intra-Cellular Therapies, Inc. (ITCI) | $86,177,559 | 48 | 44.65% | $13.97B |
ITCI Institutional Investors: Active Positions
| Increased Positions | 207 | +53.49% | 7M | +7.68% |
| Decreased Positions | 170 | -43.93% | 5M | -5.59% |
| New Positions | 70 | New | 2M | New |
| Sold Out Positions | 32 | Sold Out | 469,837 | Sold Out |
| Total Postitions | 424 | +9.56% | 98M | +2.09% |
ITCI Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Fmr Llc | $1.42M | 10.45% | 11.08M | -45,207 | -0.41% | 2024-12-31 |
| Vanguard Group Inc | $1.25M | 9.17% | 9.72M | +93,107 | +0.97% | 2024-12-31 |
| Blackrock, Inc. | $783,651.00 | 5.77% | 6.11M | -106,354 | -1.71% | 2024-12-31 |
| Jpmorgan Chase & Co | $657,165.00 | 4.84% | 5.13M | -160,193 | -3.03% | 2024-12-31 |
| Wasatch Advisors Lp | $416,499.00 | 3.07% | 3.25M | -599,767 | -15.58% | 2024-12-31 |
| Norges Bank | $411,902.00 | 3.03% | 3.21M | +1M | +65.3% | 2024-12-31 |
| Invesco Ltd. | $394,494.00 | 2.9% | 3.08M | +87,582 | +2.93% | 2024-12-31 |
| Avoro Capital Advisors Llc | $391,010.00 | 2.88% | 3.05M | 0 | 0% | 2024-12-31 |
| Bellevue Group Ag | $312,839.00 | 2.3% | 2.44M | -45,387 | -1.83% | 2024-12-31 |
| Deep Track Capital, Lp | $256,400.00 | 1.89% | 2M | +399,307 | +24.95% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.